EGFR and central nervous system cancer: Erlotinib, a selective EGFR inhibitor, can significantly inhibit the proliferation of glioma cells with the EGFRvIII mutation by reducing EGFRvIII kinase activity [11], and it has been observed that erlotinib has a good therapeutic effect on adult high-grade gliomas [12].